Press Release
Kowloon, Hong Kong, [14 July 2026]: With the continued advancement of the global cell and gene therapy market, the Xellera Therapeutics company is drawing attention to the increasing role of cell therapy manufacturing services in ensuring the development of safe, efficient and commercially attractive allogeneic treatments. The company is expanding its competencies in order to assist biotech companies, research organizations and health care innovators to fast track their way from lab research to manufacturing.
Supporting Innovation Through Advanced Manufacturing Capabilities
Xellera offers complete cell therapy manufacturing solutions which cover all stages from process development to GMP manufacturing, quality control, and bioanalytical testing. The company’s manufacturing facility is equipped to manufacture more than one product at once while ensuring that it complies with international regulatory requirements such as cGMP, FDA, EMA, and PIC/S regulations.
Growing Demand for iPSC Manufacturing Services
One of the major breakthroughs in regenerative medicine is the increasing utilization of induced pluripotent stem cells (iPSCs). The iPSC manufacturing capabilities provided by Xellera help create iPSC lines and haplobanks, which serve as a reliable resource for future use of allogeneic treatments.
Strengthening the Future of Allogeneic Cell Therapy
The industry expects that allogeneic therapies will have an increasingly significant role in the treatment of cancer, auto-immune disease, and degenerative conditions in the years to come. The success of these therapies will depend on efficient manufacturing platforms that can ensure product quality in light of increasing production requirements.
Message from the Managing Director
“The future of regenerative medicine depends on manufacturing platforms that deliver consistency, scalability, and uncompromising quality. At Xellera, we continue to invest in advanced technologies and scientific expertise that enable our partners to translate innovative research into therapies with the potential to improve patient outcomes worldwide. Our commitment is to support the next generation of allogeneic and iPSC-based therapies with reliable manufacturing solutions that meet global regulatory expectations.”
Message from the Marketing Team
The fast progress in cell and gene therapy technology creates new chances for researchers and biotech firms worldwide. We are aimed at providing high-quality, flexible services of manufacturing to make your development journey easier. Through active collaboration with our partners, we try to push forward innovations and get closer to developing effective therapies for patients.
About Xellera Therapeutics
Xellera Therapeutics is a well-known company in the cell therapy manufacturing services sphere of development and manufacturing of cell and gene therapies. Located in Hong Kong, the company was founded in 2018 and has Hong Kong’s first commercial cGMP manufacturing facilities for advanced therapy medicinal products.
Media Contact
Email: [email protected]
Phone: +852 2618 3356
Website: https://www.xelleratherapeutics.com
Address: Unit 1801, 09-16, 18/F, Millennium City 5, 418 Kwun Tong Road, Kowloon, Hong Kong
